Get to know our people and story
DoseVue was founded in 2013 as the first spin-off of the Belgian Nuclear Research Center (SCK•CEN), an internationally renowned player in the field of radiation protection and dosimetry research. Together with academic and industry partners (including SIT and Eckert Ziegler), we are continually expanding our product portfolio of in-vivo dosimetry solutions. With the dedicated support of our investors Innovation Fund and LRM, DoseVue is led by an experienced management team and board of directors.
Dirk Verellen, PhD
Dr. Dirk Verellen is a Professor at Antwerp University and Head of Medical Physics at the Iridium Cancer Network Antwerp. Dr. Verellen received his Ph.D. in medical sciences from the VUB and is the author of over 150 peer-reviewed scientific papers, editor or contributing author of several books, and has served in the board of editors for multiple scientific journals. At the European Society for Radiotherapy and Oncology (ESTRO), he serves as treasurer and member of the Board of Directors in the Physics Committee and the Radiation Oncology Safety Committee, and is a course director at the ESTRO School of Radiotherapy and Oncology. Dr. Verellen’s main interests include practical implementation of conformal radiotherapy and image-guidance in a clinical environment, and safety and quality management in radiotherapy.
Dr. Charles Scarantino
Dr. Charles Scarantino is a radiation oncologist affiliated with the University of North Carolina at Chapel Hill, NC as Emeritus Faculty. Dr. Scarantino has been in clinical practice for over three decades and has over forty publications in clinical and basic cell research. He completed a PhD in Cell Physiology at St. John’s University, Medical Degree from Bowman Gray School of Medicine of Wake Forest University, Residency and Fellowship training in Radiation Oncology at the University of Rochester. In addition to his clinical practice, he has focused on applying basic research techniques to predict response to oncotherapy and has co-founded two startup companies in this field: Sicel Technology and Lucerno Dynamics.
Board of Directors
Staf Van Reet
Chairman of the board, Senior Executive
Dr. Staf Van Reet is the Managing Director of VIZIPhar Biosciences. Staf was formerly active as Managing Director of Janssen Pharmaceutica, Head of R&D of the Janssen Group and a member of the Group Operating Committee of the pharmaceutical sector of Johnson & Johnson. From 2000 – 2004, Staf was Vice President of the Johnson & Johnson Development Corporation, the venture capital arm of Johnson & Johnson. He was a co-founder and Chairman of the Board of Directors of Movetis until the company was acquired by Shire Holdings in 2010. Currently, Staf is Chairman of the Board of Directors of Thrombogenics, Actogenix and the Flemish Institute for Biotechnology (VIB) and a Director of Biocartis and Therasolve. Staf obtained his Master and PhD in Bio-engineering Sciences from KU Leuven.